Xellia's delayed factory now up and running

2020 revenue at Xellia Pharmaceuticals, a part of the Novo group, took a beating from the delayed commissioning of its US factory. Now, however, the first batch of medication has left the building.

Coloplast drops prior skepticism, agrees to divulge national tax information

After having taken a skeptical position on disclosing how much money Coloplast makes in each country where it operates, the company has now shifted its stance on the matter. Effective from the annual report's release in November, Denmark's largest medical technology company will be more transparent about its tax payments.

New GN device to open giant market for mild hearing loss

With the launch of hybrid product Jabra Enhance Plus, developed by GN Hearing alongside group affiliate GN Audio, the hope is to pry open a hitherto unaddressed market for people with mild hearing loss worth USD 50m solely in the US. However, it will be a long and tough process, notes GN Hearing CEO Gitte Aabo.

GN Hearing disappoints despite high Q2 growth – maintains annual guidance

The hearing aid supplier notes a high level of growth in the second quarter of the year following last year's headwinds during the same period. However, despite revenue surging ahead, the operating margin underperforms, contrary to analyst estimates. GN Hearing maintains its financial outlook for the year.

Covid-stricken US still causing Lundbeck problems

While sales growth of Lundbeck's core products has stabilized well in Europe and international markets following Covid-19's peak, sales of several products in the US are still lagging – and the setback from Northera was bigger than foreseen.

1 - 25 of 140

Latest news

See all jobs